Furthermore, SNHG6 knockdown improved 5-FU therapy and resulted in a higher tumor growth inhibition rate (Fig. 2g–j), which indicates that SNHG6 might enhance 5-FU resistance in CRC cells in vivo. The gene discussed is SNHG6; the disease is colorectal carcinoma.